Pharmacology of Second Messengers: A Critical Appraisal

References

• Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N. Genistein, a specific inhibitor of tyrosine-specific protein kinase. J. Biol. Chem. 1987; 262: 5592–5595
   PubMed Web of Science ®Google Scholar
• Allgaier C, Choi B K, Hertting G. Forskolin modulates acetylcholine release in the hippocampus independently of adenylate cyclase activation. Eur. J. Pharmacol. 1990; 181: 279–282
   PubMed Web of Science ®Google Scholar
• Allison J H, Blisner M E. Inhibition of the effect of lithium on brain inositol by atropine and scopolamine. Biochem. Biophys. Res. Commun. 1976; 68: 1332–1336
   PubMed Web of Science ®Google Scholar
• Allison J H, Blisner M E, Holland W H, Hipps P P, Sherman W R. Increased brain myo-inositol I-phosphate in lithium-treated rats. Biochem. Biophys. Res. Commun. 1976; 71: 664–670
   PubMed Web of Science ®Google Scholar
• Allison J H, Stewart M A. Reduced brain inositol in lithium-treated rats. Nature (New Biol.) 1971; 233: 267–268
   PubMed Web of Science ®Google Scholar
• Ally S, Tortora G, Clair T, Grieco D, Merlo G, Katsaros D. Selective modulation of protein kinase isozymes by the site-selective analog 8-chloroadenosine 3′,5′-cyclic monophosphate provides a biological means for control of human colon cancer cell growth. Proc. Natl. Acad. Sci. USA 1988; 85: 6319–6322
   PubMed Web of Science ®Google Scholar
• Alousi A A, Johnson D C. Pharmacology of the bipyridines: Amrinone and milrinone. Circulation 1986; 73 (Suppl. 3): 11110–11124
   Google Scholar
• Alousi A A, Stankus G P, Stuart J C, Walton L H. Characterization of the cardiotonic effects of milrinone, a new and potent cardiac bipyridine, on isolated tissues from several animal species. J. Cardiovasc. Pharmacol. 1983; 5: 804–811
   PubMed Web of Science ®Google Scholar
• Anden N, Strombom U, Svensson T H. Dopamine and noradrenaline receptor stimulation: Reversal of reserpine-induced suppression of motor activity. Psychopharmacologia 1972; 29: 289–298
   Google Scholar
• Ariens E J, Wuis E W. Bias in pharmacokinetics and clinical pharmacology. Clin. Pharmacol. Ther. 1987; 42: 361–363
   PubMed Web of Science ®Google Scholar
• Askew B M. A simple screening procedure for imipramine-like antidepressant agents. Life Sci. 1963; 2: 725–730
   Google Scholar
• Avissar S, Schreiber G, Danon A, Belmaker R H. Lithium inhibits adrenergic and cholinergic increases in GTP binding in rat cortex. Nature 1988; 331: 440–442
   PubMed Web of Science ®Google Scholar
• Baginsky I, Commerçon A, Tocqué B, Colson G, Zerial A. Selective inhibition of tyrosine protein kinase by a synthetic multisubstrate analog. Biochem. Biophys. Res. Commun. 1989; 165: 1324–1330
   PubMed Web of Science ®Google Scholar
• Balla T, Enyedi P, Hunyady L, Spat A. Effects of lithium on angiotensinstimulated phosphatidylinositol turnover and aldosterone production in adrenal glomerulosa cells: A possible causal relationship. FEBS Lett. 1984; 171: 179–182
   PubMed Web of Science ®Google Scholar
• Bandurco V T, Schwender C F, Bell S C, Combs D W, Kanojia R M, Levine S D. Synthesis and cardiotonic activity of a series of substituted 4-alkyl-2(1H)-quinazolinones. J. Med. Chem. 1987; 30: 1421–1426
   PubMed Web of Science ®Google Scholar
• Bar H. Cyclic nucleotides and smooth muscle. Adv. Cyclic Nucleotide Res. 1974; 4: 195–237
   PubMedGoogle Scholar
• Baraban J M, Worley P F, Snyder S H. Second messenger systems and psychoactive drug action: Focus on the phosphoinositide system and lithium. Am. J. Psychiatry 1989; 146: 1251–1260
   PubMed Web of Science ®Google Scholar
• Barbacid M. ras Genes. Annu. Rev. Biochem. 1987; 56: 779–827
   PubMed Web of Science ®Google Scholar
• Barkai A I. Myo-inositol turnover in the intact rat brain: Increased production after d-amphetamine. J. Neurochem. 1981; 36: 1485–1491
   PubMed Web of Science ®Google Scholar
• Barrett D, Breslau N, Wax M B, Molinoff P B, Downs RWJ. New form of pseudohypoparathyroidism with abnormal catalytic adenylate cyclase. Am. J. Physiol. 1989; 257: E277–E283
   PubMed Web of Science ®Google Scholar
• Batty I, Nahorsky S R. Differential effects of lithium on muscarinic receptor stimulation of inositol phosphates in rat cerebral cortex slices. J. Neurochem. 1985; 45: 1514–1521
   PubMed Web of Science ®Google Scholar
• Baum C L, Wali R K, Sitrin M D, Bolt MJG, Brasitus T A. 1,2-Dimethylhydrazine-induced alterations in protein kinase C activity in the rat preneoplastic colon. Cancer Res. 1990; 50: 3915–3920
   PubMed Web of Science ®Google Scholar
• Beavo J A, Reifsnyder D H. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol. Sci. 1990; 11: 150–155
   PubMed Web of Science ®Google Scholar
• Beavo J A, Rogers N L, Crofford O B, Hardman J G, Sutherland E W, Newman E V. Effects of xanthine derivatives on lipolysis and on adenosine 3′,5′-monophosphate phosphodiesterase activity. Mol. Pharmacol. 1970; 6: 597–603
   PubMed Web of Science ®Google Scholar
• Benfey B G, Kunos G, Nickerson M. Dissociation of cardiac inotropic and adenylate cyclase activating adrenoceptors. Br. J. Pharmacol. 1974; 51: 253–257
   PubMed Web of Science ®Google Scholar
• Benigni A, Gregorini G, Frusca T, Chiabrando C, Ballerini S, Valcamonico A. Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy-induced hypertension. N. Engl. J. Med. 1989; 321: 357–362
   PubMed Web of Science ®Google Scholar
• Bennett C F, Balcarek J M, Varrichio A, Crooke S T. Molecular cloning and complete amino-acid sequence of form-I phosphoinositide-specific phospholipase C. Nature 1988; 334: 268–270
   PubMed Web of Science ®Google Scholar
• Béréziat G, Etienne J, Kokkinidis M, Olivier J L, Pernas P. New trends in mammalian non-pancreatic phospholipase A2 research. J. Lipid Mediators 1990; 2: 159–172
   PubMedGoogle Scholar
• Bergstrand H, Kristofferson J, Lundquist B, Schurmann A. Effects of antiallergic agents, compound 48/80, and some reference inhibitors on the activity of partially purified human lung tissue adenosine cyclic 3′,5′-monophosphate and guanosine cyclic 3′,5′-monophosphate phosphodiesterases. Mol. Pharmacol. 1977; 13: 38–43
   PubMed Web of Science ®Google Scholar
• Bergstrand H, Lundquist B. Partial purification and characterization of adenosine- and guanosine-3′,5′-monophoshate phosphodiesterases from human lung tissue. Biochemistry 1976; 15: 1727–1735
   PubMed Web of Science ®Google Scholar
• Bergstrand H, Lundquist B, Schurmann A. Cyclic nucleotide phosphodiesterase. Partial purification and characterization of a high affinity enzyme activity from human lung tissue. J. Biol. Chem. 1978; 253: 1881–1891
   PubMed Web of Science ®Google Scholar
• Bernal S D, Lampidis T J, McLsaac R M, Chen L B. Anticarcinoma activity in vivo of Rhodamine 123, a mitochondrial-specific dye. Science 1983; 222: 169–172
   PubMed Web of Science ®Google Scholar
• Berridge M J, Downes C P, Hanley M R. Lithium amplifies agonistdependent phosphatidylinositol responses in brain and salivary glands. Biochem. J. 1982; 206: 587–595
   PubMed Web of Science ®Google Scholar
• Berridge M J, Downes C P, Hanky M R. Neural and developmental actions of lithium: A unifying hypothesis. Cell 1989; 59: 411–419
   PubMed Web of Science ®Google Scholar
• Berridge M J, Irvine R F. Inositol trisphosphate, a novel second messenger in cellular signal transduction. Nature 1984; 312: 315–321
   PubMed Web of Science ®Google Scholar
• Bethke T, Brunkhorst D, von der Leyen H, Meyer W, Nigbur R, Scholz H. Mechanism of action and cardiotonic activity of a new phosphodiesterase inhibitor, the benzimidazole derivative adibendan (BM 14.478) in guinea-pig hearts. Naunyn Schmiedebergs Arch. Pharmacol. 1988; 337: 576–582
   PubMed Web of Science ®Google Scholar
• Bethke T, Meyer W, Schmitz W, Scholz H, Thomas K, Wenzlaff H. Phosphodiesterase III inhibition by MCI-154 and other cardiotonic drugs in relation to force of contraction, cAMP content and calcium sensitization in the heart. Eur. J. Pharmacol. 1990; 183: 783–784
   Web of Science ®Google Scholar
• Bhat S V, Bajwa B S, Dornaeur H, De Souza N J, Fehlhaber H W. Structures and stereochemistry of new labdane diterpenoids from Coleus forskohlii Briq. Tetrahedon Lett. 1977; 19: 1669–1672
   Google Scholar
• Birnbaumer L. G proteins in signal transduction. Annu. Rev. Pharmacol. Toxicol. 1990; 30: 675–705
   PubMed Web of Science ®Google Scholar
• Bohm M, Schmitz W, Scholz H. Evidence against a role of a pertussis toxin-sensitive guanine nucleotide-binding protein in the alphaladrenoceptor-mediated positive inotropic effect in the heart. Naunyn Schmiedebergs Arch. Pharmacol. 1987; 335: 476–479
   PubMed Web of Science ®Google Scholar
• Bourin M, Poncelet M, Chermat R, Simon P. The value of the reserpine test in psychopharmacology. Arzneimittelforschung 1983; 33: 1173–1176
   PubMed Web of Science ®Google Scholar
• Bourne H R, Sanders D A, McCormick F. The GTPase superfamily: A conserved switch for diverse cell functions. Nature 1990; 348: 125–132
   PubMed Web of Science ®Google Scholar
• Braunwald E, Colucci W S. Evaluating the efficacy of new inotropic agents. J. Am. Coll. Cardiol. 1984; 3: 1570–1574
   PubMed Web of Science ®Google Scholar
• Breitwieser G E, Szabo G. Uncoupling of cardiac muscarinic and β-adrenergic receptors from ion channels by a guanine nucleotide analogue. Nature 1985; 317: 538–540
   PubMed Web of Science ®Google Scholar
• Brown L, Nabauer M, Erdmann E. The positive inotropic response to milrinone in isolated human and guinea pig myocardium. Naunyn Schmiedebergs Arch. Pharmacol. 1986; 3334: 196–201
   Google Scholar
• Bruckner R, Hackbarth I, Meinertz T, Schmelzle B, Scholz H. The positive inotropic effect of phenylephrine in the presence of propranolol. Increase in time to peak force and in relaxation time without increase in c-AMP. Naunyn Schmiedebergs Arch. Pharmacol. 1978; 303: 205–211
   PubMed Web of Science ®Google Scholar
• Brunkhorst D, von der Leyen H, Meyer W, Nigbur R, Schmidt-Schumacher C, Scholz H. Relation of positive inotropic and chronotropic effects of pimobendan, UD-CG 212 CI, milrinone and other phosphodiesterase inhibitors to phosphodiesterase III inhibition in guinea-pig heart. Naunyn Schmiedebergs Arch. Pharmacol. 1989; 339: 575–583
   PubMed Web of Science ®Google Scholar
• Brunkhorst D, von der Leyen H, Meyer W, Schmidt-Schumacher C, Scholz H. Selective inhibition of cAMP phosphodiesterase III activity by the cardiotonic agent saterinone in guinea pig myocardium. Arzneimittelforschung 1988; 38: 1293–1298
   PubMed Web of Science ®Google Scholar
• Carlsson A. Drugs which block the storage of 5-hydroxytryptamine and related amines. 19. Handbook of Experimental Pharmacology, O Eichler, A Farah. Springer-Verlag, Berlin 1967; 529–592
   Google Scholar
• Carlsson A, Lindqvist M, Magnusson T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957; 180: 1200
   PubMed Web of Science ®Google Scholar
• Casebolt T L, Jope R S. Chronic lithium treatement reduces norepinephrine-stimulated inositol phospholipid hydrolysis in rat cortex. Eur. J. Pharmacol. 1987; 140: 245–246
   PubMed Web of Science ®Google Scholar
• Cavins J A, Hall T C, Olson K B, Khung C L, Horton J, Colsky J. Initial toxicity study of sangivamycin (NSC-65346). Cancer Chemother. Rep. 1967; 51: 197–200
   PubMedGoogle Scholar
• Cerletti C, Gambino M C, Bucchi F, de Gaetano G. Comparison of the effects of oral versus intravenous aspirin on platelet, vascular, and renal prostanoid generation. 17. Advances in Prostaglandins, Thromboxane, and Leukotriene Research, B Samuelsson, R Paoletti, PW Ramwell. Raven Press, New York 1987; 244–247
   Google Scholar
• Cerletti C, Gambino M C, Garattini S, de Gaetano G. Biochemical selectivity of oral versus intravenous aspirin in rats. Inhibition by oral aspirin of cyclooxygenase activity in platelets and presystemic but not systemic vessels. J. Clin. Invest. 1986; 78: 323–326
   PubMed Web of Science ®Google Scholar
• Cervo L, Grignaschi G, Samanin R. The role of the mesolimbic dopaminergic system in the desipramine effect in the forced swimming test. Eur. J. Pharmacol. 1990; 178: 129–133
   PubMed Web of Science ®Google Scholar
• Cervo L, Samanin R. Evidence that dopamine mechanisms in the nucleus accumbens are selectively involved in the effect of desipramine in the forced swimming test. Neuropharmacology 1987; 26: 1469–1480
   PubMed Web of Science ®Google Scholar
• Charp P A, Rice W G, Raynor R L, Reimund E, Kinkade JMJ, Ganz T. Inhibition of protein kinase C by defensins, antibiotic peptides from human neutrophils. Biochem. Pharmacol. 1988; 37: 951–956
   PubMed Web of Science ®Google Scholar
• Chen L B, Weiss M J, Davis S, Bleday R S, Wong J R, Song J. Mitochondria in living cells: Effects of growth factors and tumor promoters, alterations in carcinoma cells, and targets for therapy. Cancer Cells Growth Factors and Transformation, J Feramisco, B Ozanne, C Stiles. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 1985; vol. 3: 433–443
   Google Scholar
• Chesebro J H, Browne M A, Fenster P E, Garland W T, Konstam M A. The hemodynamic effects of chronic oral milrinone therapy: A multi-center controlled trial. J. Am. Coll. Cardiol. 1988; 11: 144A
   Google Scholar
• Chiabrando C, Castelli M G, Cozzi E, Fanelli R, Campoleoni A, Balotta C. Antiinflammatory action of salicylates: Aspirin is not a prodrug for salicylate against rat carrageenin pleurisy. Eur. J. Pharmacol. 1989; 159: 257–264
   PubMed Web of Science ®Google Scholar
• Cho-Chung Y S. Cyclic AMP and mammary tumor regression. Cell Mol. Biol. 1980; 26: 395–403
   Web of Science ®Google Scholar
• Cho-Chung Y S. Site-selective 8-chloro-cyclic adenosine 3′,5′-monophosphate as a biologic modulator of cancer: Restoration of normal control mechanisms. J. Natl. Cancer Inst. 1989; 81: 982–987
   PubMed Web of Science ®Google Scholar
• Choraria S K, Taylor D, Pitcher J. Double-blind crossover comparison of enoximone and placebo in patients with congestive heart failure. Circulation 1987; 76: 1307–1311
   PubMed Web of Science ®Google Scholar
• Coates W J, Eden R I, Emmett J C, Gristwood R W, Owen DAA, Slater R A. SK & F 94120, a novel agent with positive inotropic and vasodilator activity. Br. J. Pharmacol. 1985; 84(suppl): 22P
   Google Scholar
• Colman R F. Affinity labeling of purine nucleotide sites in proteins. Annu. Rev. Biochem. 1983; 52: 67–91
   PubMed Web of Science ®Google Scholar
• Colucci W S, Wright R F, Braunwald E. New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. N. Engl. J. Med. 1986; 314: 290–299
   PubMed Web of Science ®Google Scholar
• Combs D W, Rampulla M S, Bell S C, Klaubert D H, Tobia A J, Falotico R. 6-Benzoxazinylpyridazin-3-ones: Potent, long-acting positive inotrope and peripheral vasodilator agents. J. Med. Chem. 1990; 33: 380–386
   PubMed Web of Science ®Google Scholar
• Coombs J, Thompson S. Forskolin's effect on transient K current in nudibranch neurons is not reproduced by cAMP. J. Neurosci. 1987; 7: 443–452
   PubMed Web of Science ®Google Scholar
• Coppen A. The biochemistry of affective disorders. Br. J. Psychiatry 1967; 113: 1237–1264
   PubMed Web of Science ®Google Scholar
• Costa E, Gerattini S, Valzelli L. Interactions between reserpine, chlorpromazine and imipramine. Experientia 1960; 16: 461–465
   PubMedGoogle Scholar
• Cottier C, Follath F, Kiowski W, Pfisterer M, Emmenegger H, Burkart F. Acute hemodynamic effects of MDL 19205 in mild congestive heart failure. J. Cardiovasc. Pharmacol. 1987; 9: 209–212
   PubMed Web of Science ®Google Scholar
• Dage R C, Roebel L E, Hsieh C P, Weiner D L, Woodward J K. Cardiovascular properties of a new cardiotonic agent: MDL 17,043 (1,3-dihydro-4-methyl-5-[4-(methyltio)-benzoyl]-2H-imidazol-2-one). J. Cardiovasc. Pharmacol. 1982; 4: 500–508
   PubMed Web of Science ®Google Scholar
• Dage R C, Roebel L E, Gibson J P, Okerholm R A, Rolf C N. Enoximone. New Cardiovascular Drugs, A Scriabine. Raven Press, New York 1986; 63–79
   Google Scholar
• Dale I L, Bradshaw T D, Gescher A, Pettit G R. Comparison of effects of bryostatins 1 and 2 and 12-O-tetradecanoylphorbol-13-acetate on protein kinase C activity in A549 human lung carcinoma cells. Cancer Res. 1989; 49: 3242–3245
   PubMed Web of Science ®Google Scholar
• Daly P A, Chatterjee K, Viquerat C E, Parmley W W, Curran D, Scheinbaum M. R013–6438, a new inotrope-vasodilator: Systemic and coronary hemodynamic effects in congestive heart failure. Am. J. Cardiol. 1985; 55: 1539–1544
   PubMed Web of Science ®Google Scholar
• Davies G E. Antibronchoconstrictor activity of two new phosphodiesterase inhibitors, a triazolopyrazine (ICI 58 301) and a triazolopyrimidine (ICI 63 197). J. Pharm. Pharmacol. 1973; 25: 681–689
   PubMed Web of Science ®Google Scholar
• Davis C W. Assessment of selective inhibition of rat cerebral cortical calcium-independent and calcium-dependent phosphodiesterases in crude extracts using deoxycyclic AMP and potassium ions. Biochim. Biophys. Acta 1984; 797: 354–362
   PubMed Web of Science ®Google Scholar
• Davis P D, Hill C H, Keech E, Lawton G, Nixon J S, Sedgwick A D. Potent selective inhibitors of protein kinase C. FEBS Lett. 1989; 259: 61–63
   PubMed Web of Science ®Google Scholar
• Davis R J, Czech M P. Amiloride directly inhibits growth factor receptor tyrosine kinase activity. J. Biol. Chem. 1985; 260: 2543–2551
   PubMed Web of Science ®Google Scholar
• Dean N M, Kanemitsu M, Boynton A L. Effects of the tyrosinekinase inhibitor genistein on DNA synthesis and phospholipid-derived second messenger generation in mouse 10T fibroblasts and rat liver T51 B cells. Biochem. Biophys. Res. Commun. 1989; 165: 795–801
   PubMed Web of Science ®Google Scholar
• DeBortoli M E, Abou-Issa H, Haley B E, Cho-Chung Y S. Amplified expression of p21 ras protein in hormone-dependent mammary carcinomas of humans and rodents. Biochem. Biophys. Res. Commun. 1985; 127: 699–706
   PubMed Web of Science ®Google Scholar
• de Chaffoy de Courcelles D, Roevens P, Van Belle H. R 59 022, a diacylglycerol kinase inhibitor. J. Biol. Chem. 1985; 260: 15762–15770
   PubMedGoogle Scholar
• de Gaetano G, Bertelé V, Cerletti C. Mechanism of action and clinical use of prostanoids. Critical Leg Ischaemia. Its Pathophysiology and Management, JA Dormandy, G Stock. Springer-Verlag, Berlin 1990; 117–137
   Google Scholar
• de Gaetano G, Cerletti C, Dejana E, Latini R. Pharmacology of plate-let inhibition in humans: Implications of the salicylate-aspirin interaction. Circulation 1985; 72: 1185–1193
   PubMed Web of Science ®Google Scholar
• de Haen C, Nist B J, Hansen R S, Johnson D G, Thompson W J. 2,4-Diamino-5-cyano-6-halopyridines: A new class of cyclic AMP phosphodiesterase inhibitors with therapeutic potential. Biochem. Pharmacol. 1984; 33: 2109–2113
   PubMed Web of Science ®Google Scholar
• De Montis G M, Devoto P, Meloni D, Saba P, Tagliamonte A. Receptors modulation by chronic imipramine treatment. Eur. J. Pharmacol. 1990; 183: 2055
   Web of Science ®Google Scholar
• DeRubertis F R, Craven P A. Early alterations in rat colonic mucosal cyclic nucleotide metabolism and protein kinase activity induced by 1,2-dimethylhydrazine. Cancer Res. 1980; 40: 4589–4598
   PubMed Web of Science ®Google Scholar
• DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant R, Wright R. Oral milrinone and digoxin in heart failure: Results of a placebo-controlled, prospective trial of each agent and the combination. Circulation 1987; 76: IV-256, 1020, (suppl. IV) abst. n.
   Web of Science ®Google Scholar
• Di Cerbo A, Di Girolamo M, Guardabasso V, De Filippis V, Corda D. Immunoglobulins from Graves' disease stimulate phospholipase A2 in FRTL5 thyroid cells. J. Clin. Endocrinol. Metab. 1992, in press
   PubMed Web of Science ®Google Scholar
• Di Cerbo A, Di Girolamo M, De Filippis V, Di Filippo C, Corda D. Immunoglobulins from Graves' patients stimulate arachidonic acid release in FRTL5 cells. Cell Biol. Int. Rep. 1990; 14, suppl., 243
   Google Scholar
• Diomede L, Bizzi A, Magistrelli A, Modest E J, Salmon M, Noseda A. Role of cell cholesterol in modulating antineoplastic ether lipid uptake, membrane effects and cytotoxicity. Int. J. Cancer 1990; 46: 341–346
   PubMed Web of Science ®Google Scholar
• Drexler H G, Gignac S M, Jones R A, Scott C S, Pettit G R, Hoffbrand A V. Bryostatin 1 induces differentiation of B-chronic lymphocytic leukemia cells. Blood 1989; 74: 1747–1757
   PubMed Web of Science ®Google Scholar
• Drummond A H. Lithium affects G-protein receptor coupling. Nature 1988; 331: 388
   PubMed Web of Science ®Google Scholar
• Dubey M P, Srimal R C, Nityanand S, Dhawan B N. Pharmacological studies on coleonol, a hypotensive diterpene from. Coleus forskohlii. J. Ethnopharmacol. 1981; 3: 1–13
   PubMed Web of Science ®Google Scholar
• Endoh M, Brodde O, Schumann H J. Relationship between the level of cAMP and the contractile force under stimulation of α- and β-adrenoceptors by phenylephrine in the isolated rabbit papillary muscle. Naunyn Schmiedebergs Arch. Pharmacol. 1976; 295: 109–115
   PubMed Web of Science ®Google Scholar
• Epstein P M, Strada S J, Sarada K, Thompson W J. Catalytic and kinetic properties of purified high-affinity cyclic AMP phosphodiesterase from dog kidney. Arch. Biochem. Biophys. 1982; 218: 119–133
   PubMed Web of Science ®Google Scholar
• Etoh S, Ohashi M, Baba A, Iwata H. Ibudilast inhibits inositolphosphates formation in guinea pig lung. Eur. J. Pharmacol. 1990; 183: 761–762
   Web of Science ®Google Scholar
• Evans D B. Overview of cardiovascular physiologic and pharmacologic aspects of selective phosphodiesterase peak III inhibitors. Am. J. Cardiol. 1989; 63: 9A–11A
   PubMed Web of Science ®Google Scholar
• Evans D B, Potoczak R E, Steffen R P. Cardiovascular pharmacology of the cardiotonic, imazodan (CI-914). Drug Dev. Res. 1986; 9: 143–157
   Web of Science ®Google Scholar
• Evans D B, Steffen R P, Potoczak R E, Weishaar R E, Kaplan H R. Cardiovascular effects of the novel cardiotonic, CI-930. Pharmacologist 1984; 26: 165
   Google Scholar
• Fain J N, Berridge M J. Relationship between phosphatidylinositol synthesis and recovery of 5-hydroxytryptamine-responsive Ca9+ flux in blowfly salivary glands. Biochem. J. 1979; 180: 655–661
   PubMed Web of Science ®Google Scholar
• Falotico R, Moore J B, Bandurco V, Bell S C, Levine S D, Tobia A J. Cardiovascular properties of bemarinone: A new orally active quinazolinone cardiotonic agent. Drug Dev. Res. 1988; 12: 241–257
   Web of Science ®Google Scholar
• Feldman A M, Cates A E, Veazey W B, Hershberger R E, Bristow M R, Baughman K L. Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. J. Clin. Invest. 1988; 82: 189–197
   PubMed Web of Science ®Google Scholar
• Ferrigni N R, McLaughlin J L, Powell R G, Smith CRJ. Use of potato disc and brine shrimp bioassays to detect activity and isolated piceatannol as the antileukemic principle from the seeds of euphorbia lagascae. J. Nat. Prod. 1984; 47: 347–352
   PubMed Web of Science ®Google Scholar
• Flint A J, Paladini R D, Koshland DEJ. Autophosphorylation of protein kinase C at three separated regions of its primary sequence. Science 1990; 249: 408–411
   PubMed Web of Science ®Google Scholar
• Flower R J. Lipocortin and the mechanism of action of the glucocorticoids. Br. J. Pharmacol. 1988; 94: 987–1015
   PubMed Web of Science ®Google Scholar
• Fredholm B B. On the mechanism of action of theophylline and caffeine. Acta Med. Scand. 1985; 217: 149–153
   PubMed Web of Science ®Google Scholar
• Freund P, Muller-Beckmann B, Strein K, Kling L, Ruegg C. Ca2+- sensitizing effect of BM 14.478 on skinned cardiac muscle fibres of guinea-pig papillary muscle. Eur. J. Pharmacol. 1987; 136: 243–246
   PubMed Web of Science ®Google Scholar
• Gambino M C, Passaghe S, Chen Z M, Bucchi F, Gori G, Latini R. Selectivity of oral aspirin as an inhibitor of platelet vs. vascular cyclooxygenase activity is reduced by portacaval shunt in rats. J. Pharmacol. Exp. Ther. 1988; 245: 287–290
   PubMed Web of Science ®Google Scholar
• Ganz T, Selsted M E, Szklarek D, Harwig SSL, Daher K, Bainton D F. Defensins. Natural peptide antibiotics of human neutrophils. J. Clin. Invest. 1985; 76: 1427–1435
   PubMed Web of Science ®Google Scholar
• Garattini S. Perspectives in the treatment of cancer metastasis. Clin. Exp. Metastasis 1987; 5: 105–124
   PubMed Web of Science ®Google Scholar
• Garattini S, Jori A. Interactions between imipramine-like drugs and reserpine on body temperature. Anti-Depressant Drugs, S Garattini, MNG Dukes. Excerpta Medica, Amsterdam 1967; 179–192
   Google Scholar
• Garattini S, Pujol J F, Samanin R. Interactions Between Putative Neurotransmitters in the Brain. Raven Press, New York 1978
   Google Scholar
• Garattini S, Samanin R. Biochemical hypotheses on antidepressant drugs: A guide for clinicians or a toy for pharmacologists. Psychol. Med. 1988; 18: 287–304
   PubMed Web of Science ®Google Scholar
• Gautam N, Northup J, Tamir H, Simon M I. G protein diversity is increased by associations with a variety of g subunits. Proc. Natl. Acad. Sci. USA 1990; 87: 7973–7977
   PubMed Web of Science ®Google Scholar
• Gazit A, Yaish P, Gilon C, Levitzki A. Tyrphostins I: Synthesis and biological activity of protein tyrosine kinase inhibitors. J. Med. Chem. 1989; 32: 2344–2352
   PubMed Web of Science ®Google Scholar
• Geahlen R L, McLaughlin J L. Piceatannol (3,4,3′,5′-tetrahydroxytrans-stilbene) is a naturally occurring protein-tyrosine kinase inhibitor. Biochem. Biophys. Res. Commun. 1989; 165: 241–245
   PubMed Web of Science ®Google Scholar
• Gehlert D R. Regional modulation of [3H]forskolin binding in the rat brain by guanylyl-5′-imidodiphosphate and sodium fluoride: Comparison with the distribution of guanine nucleotide binding sites. J. Pharmacol. Exp. Ther. 1986; 239: 952–958
   PubMed Web of Science ®Google Scholar
• Gehlert D R, Wamsley J K. In vitro autoradiographic localization of guanine nucleotide binding sites in sections of rat brain labeled with [3H]guanylyl-5′-imidodiphosphate. Eur. J. Pharmacol. 1986; 129: 169–174
   PubMed Web of Science ®Google Scholar
• Gillespie E. Anagrelide: A potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity. Biochem. Pharmacol. 1988; 37: 2866–2868
   PubMed Web of Science ®Google Scholar
• Gillespie P G, Beavo J A. Inhibition and stimulation of photoreceptor phosphodiesterases by dipyridamole and M & B 22, 948. Mol. Pharmacol. 1989; 36: 773–781
   PubMed Web of Science ®Google Scholar
• Gilman A G. G proteins and regulation of adenylyl cyclase. J. Am. Med. Assoc. 1989; 262: 1819–1825
   PubMed Web of Science ®Google Scholar
• GISSI. GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12490 patients with acute myocardial infarction. Lancet 1990a; 336: 65–71
   PubMed Web of Science ®Google Scholar
• GISSI. In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase or streptokinase with or without heparin. Lancet 1990b; 336: 71–75
   PubMed Web of Science ®Google Scholar
• Godfrey P P, McClue S J, White A M, Wood A J, Grahame-Smith D G. Subacute and chronic in vivo lithium treatment inhibits agonist- and sodium fluoride-stimulated inositol phosphate production in rat cortex. J. Neurochem. 1989; 52: 498–506
   PubMed Web of Science ®Google Scholar
• Gopalakrishna R, Barsky S H. Tumor promoter-induced membrane-bound protein kinase C regulates hematogenous metastasis. Proc. Natl. Acad. Sci. USA 1988; 85: 612–616
   PubMed Web of Science ®Google Scholar
• Guillem J G, O'Brian C A, Fitzer C J, Forde K A, LoGerfo P, Treat M. Altered levels of protein kinase C and Ca2+ -dependent protein kinases in human colon carcinomas. Cancer Res. 1987; 47: 2036–2039
   PubMed Web of Science ®Google Scholar
• Gundlach A L, Urosevic A. Autoradiographic localization of particulate cyclic AMP-dependent protein kinase in mammalian brain using [3H]cyclic AMP: Implications for organization of second messenger systems. Neuroscience 1989; 29: 695–714
   PubMed Web of Science ®Google Scholar
• Hagiwara M, Endo T, Hidaka H. Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle. Biochem. Pharmacol. 1984; 33: 453–457
   PubMed Web of Science ®Google Scholar
• Hagiwara M, Inoue S, Tanaka T, Nunoki K, Ito M, Hidaka H. Differential effects of flavonoids as inhibitors of tyrosine protein kinases and serine/threonine protein kinases. Biochem. Pharmacol. 1988; 37: 2987–2992
   PubMed Web of Science ®Google Scholar
• Hallcher L M, Sherman W R. The effects of lithium ion and other agents on the activity of myo-inositol-I-phosphatase from bovine brain. J. Biol. Chem. 1980; 255: 10896–10901
   PubMed Web of Science ®Google Scholar
• Hanks S K, Quinn A M, Hunter T. The protein kinase family: Conserved features and deduced phylogeny of the catalytic domains. Science 1988; 241: 42–52
   PubMed Web of Science ®Google Scholar
• Hannun Y A, Bell R M. Aminoacridines, potent inhibitors of protein kinase C. J. Biol. Chem. 1988; 263: 5124–5131
   PubMed Web of Science ®Google Scholar
• Hannun Y A, Foglesong R J, Bell R M. The adriamycin-iron(III) complex is a potent inhibitor of protein kinase C. J. Biol. Chem. 1989; 264: 9960–9966
   PubMed Web of Science ®Google Scholar
• Hannun Y A, Loomis C R, Merrill AHJ, Bell R M. Sphingosine inhibition of protein kinase C activity and of phorbol dibutyrate binding in vitro and in human platelets. J. Biol. Chem. 1986; 261: 12604–12609
   PubMed Web of Science ®Google Scholar
• Harrison S A, Reifsnyder D H, Gallis B, Cadd G G, Beavo J A. Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: A receptor for new cardiotonic drugs. Mol. Pharmacol. 1986; 29: 506–514
   PubMed Web of Science ®Google Scholar
• Hatori A, Shigematsu A, Tsuya A. The metabolism of aspirin in rats; localization, absorption, distribution and excretion. Eur. J. Drug Metab. Pharmacokinet. 1984; 9: 205–214
   PubMed Web of Science ®Google Scholar
• Heinsimer J A, Davies A O, Downs R W, Levine M A, Spiegel A M, Drezner M K. Impaired formation of (β-adrenergic receptor-nucleotide regulatory protein complexes in pseudohypoparathyroidism. J. Clin. Invest. 1984; 73: 1335–1343
   PubMed Web of Science ®Google Scholar
• Hennings H, Blumberg P M, Pettit G R, Herald C L, Shores R, Yuspa S H. Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin. Carcinogenesis 1987; 8: 1343–1346
   PubMed Web of Science ®Google Scholar
• Hensey C E, Boscoboinik D, Azzi A. Suramin, an anti-cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A. FEBS Len. 1989; 258: 156–158
   PubMed Web of Science ®Google Scholar
• Herling A W, Bickel M. The stimulatory effect of forskolin on gastric acid secretion in rats. Eur. J. Pharmacol. 1986; 125: 233–239
   PubMed Web of Science ®Google Scholar
• Herzig J W. Contractile proteins: Possible targets for drug action. Trends Pharmacol. Sci. 1984; 5: 296–300
   Web of Science ®Google Scholar
• Hidaka H, Asano T. Human blood platelet 3′:5′-cyclic nucleotide phosphodiesterase. Isolation of low-Km and high-Km phosphodiesterase. Biochim. Biophys. Acta 1976; 429: 485–497
   PubMed Web of Science ®Google Scholar
• Hidaka H, Endo T. Selective inhibitors of three forms of cyclic nucleotide phosphodiesterase-basic and potential clinical applications. Adv. Cyclic Nucleotide Protein Phosphorylation Res. 1984; 16: 245–259
   PubMedGoogle Scholar
• Hidaka H, Hagiwara M. Pharmacology of the isoquinoline sulfonamide protein kinase C inhibitors. Trends Pharmacol. Sci. 1987; 8: 162–164
   Web of Science ®Google Scholar
• Hidaka H, Inagaki M, Kawamoto S, Sasaki Y. Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry 1984; 23: 5036–5041
   PubMed Web of Science ®Google Scholar
• Hirata F. The regulation of lipomodulin, a phospholipase inhibitory protein, in rabbit neutrophils by phosphorylation. J. Biol. Chem. 1981; 256: 7730–7733
   PubMed Web of Science ®Google Scholar
• Hirata M, Suematsu E, Hashimoto T, Hamachi T, Koga T. Release of Ca2+ from a non-mitochondrial store site in peritoneal macrophages treated with saponin by inositol 1,4,5-trisphosphate. Biochem. J. 1984; 223: 229–236
   PubMed Web of Science ®Google Scholar
• Hirvonen M, Savolainen K. Evidence that lithium only transiently inhibits cerebral phosphoinositide metabolism. Eur. J. Pharmacol. 1990; 183: 762
   Web of Science ®Google Scholar
• Hofferber E, Jacobitz P, Armah I B. Cardiovascular actions of BDF 8634: A novel inotropic agent with selective alpha- 1 -receptor blocking actions. Naunyn Schmiedebergs Arch. Pharmacol. 1986; 333: R33
   Google Scholar
• Hoick M, Thorens S, Muggli R, Eigenmann R. Studies on the mechanism of positive inotropic activity of Ro 13–6438, a structurally novel cardiotonic agent with vasodilating properties. J. Cardiovasc. Pharmacol. 1984; 6: 520–530
   PubMed Web of Science ®Google Scholar
• Honerjager P, Heiss A, Schafer-Korting M, Schonsteiner G, Reiter M. UD-CG 115. A cardiotonic pyridazinone which elevates cyclic AMP and prolongs the action potential in guinea-pig papillary muscle. Naunyn Schmiedebergs Arch. Pharmacol. 1984; 325: 259–269
   PubMed Web of Science ®Google Scholar
• Honma Y, Okabe-Kado J, Hozumi M, Uehara Y, Mizuno S. Induction of erythroid differentiation of K562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity. Cancer Res. 1989; 49: 331–334
   PubMed Web of Science ®Google Scholar
• Hood WBJ. Controlled and uncontrolled studies of phosphodiesterase III inhibitors in contemporary cardiovascular medicine. Am. J. Cardiol. 1989; 63: 46A–53A
   PubMed Web of Science ®Google Scholar
• Horowski H, Sastre-Y-Hernandez M. Clinical effects of the neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: Global evaluation of the preliminary reports. Curr. Ther. Res. 1985; 38: 23–29
   Web of Science ®Google Scholar
• Hoshi T, Garber S S, Aldrich R W. Effect of forskolin on voltage-gated K+ channels is independent of adenylate cyclase activation. Science 1988; 240: 1652–1655
   PubMed Web of Science ®Google Scholar
• Houslay M D, Beavo J A. Isoenzymes of Cyclic Nucleotide Phosphodiesterase. Wiley, New York 1990
   Google Scholar
• Huang K P, Chan KFJ, Singh T J, Nakabayashi H, Huang F L. Auto-phosphorylation of rat brain Ca2+-activated and phospholipiddependent protein kinase. J. Biol. Chem. 1986; 261: 12134–12140
   PubMedGoogle Scholar
• Huang K P, Huang F L, Nakabayashi H, Yoshida Y. Biochemical characterization of rat brain protein kinase C isozymes. J. Biol. Chem. 1988; 263: 14839–14845
   PubMed Web of Science ®Google Scholar
• Hughes B G, Robins R K. 2′,5′-Oligoadenylates and related 2′,5′-oligonucieotide analogues. 2. Effect on cellular proliferation, protein synthesis, and endoribonuclease activity. Biochemistry 1983; 22: 2127–2135
   PubMed Web of Science ®Google Scholar
• Hunter T, Cooper J A. Protein-tyrosine kinases. Annu. Rev. Biochem. 1985; 54: 897–930
   PubMed Web of Science ®Google Scholar
• Innis R B, Aghajanian G K. Pertussis toxin blocks 5-HTIA and GABAB receptor-mediated inhibition of serotonergic neurons. Eur. J. Pharmacol. 1987; 143: 195–204
   PubMed Web of Science ®Google Scholar
• Inoue M, Kishimoto A, Takai Y, Nishizuka Y. Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. II. Proenzyme and its activation by calcium-dependent protease from rat brain. J. Biol. Chem. 1977; 252: 7610–7616
   PubMed Web of Science ®Google Scholar
• Ishitoya J, Toriyama M, Oguchi N, Kitamura K, Ohshima M, Asano K. Gene amplification and overexpression of EGF receptor in squamous cell carcinomas of the head and neck. Br. J. Cancer 1989; 59: 559–562
   PubMed Web of Science ®Google Scholar
• ISIS-2. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349–360
   PubMed Web of Science ®Google Scholar
• Isshiki K, Imoto M, Sawa T, Umezawa K, Takeuchi T, Umezawa H. Inhibition of tyrosine protein kinase by synthetic erbstatin analogs. J. Antibiot. (Tokyo) 1987; 40: 1209–1210
   PubMed Web of Science ®Google Scholar
• Iwamoto K, Takei M, Watanabe J. Gastrointestinal and hepatic first-pass metabolism of aspirin in rats. J. Pharm. Pharmacol. 1982; 34: 176–180
   PubMed Web of Science ®Google Scholar
• Iyengar R. G-proteins and the regulation of effector function. Eur. J. Pharmacol. 1990; 183: 121–122
   Web of Science ®Google Scholar
• Jafri S M, Burlew B S, Goldberg A D, Rogers A, Goldstein S. Hemodynamic effects of a new type III phosphodiesterase inhibitor (CI-914) for congestive heart failure. Am. J. Cardiol. 1986; 57: 254–259
   PubMed Web of Science ®Google Scholar
• Jafri S M, Burlew B S, Goldberg A D, Olson S, Froelich J W, Gold-Stein S. Hemodynamic, pharmacokinetic and clinical response to CI-930 in congestive heart failure due to ischemic or dilated cardiomyopathy. Am. J. Cardiol. 1987; 59: 1126–1130
   PubMed Web of Science ®Google Scholar
• Jaken S, Tashjian AHJ, Blumberg P M. Characterization of phorbol ester receptors and their down-modulation in GH4C1 rat pituitary cells. Cancer Res. 1981; 41: 2175–2181
   PubMed Web of Science ®Google Scholar
• Jalava A M, Heikkila J, Akerlind G, Pettit G R, Akerman KEO. Effects of bryostatins 1 and 2 on morphological and functional differentiation of SH-SY5Y human neuroblastoma cells. Cancer Res. 1990; 50: 3422–3428
   PubMed Web of Science ®Google Scholar
• Jefferson A B, Schulman H. Sphingosine inhibits calmodulindependent enzymes. J. Biol. Chem. 1988; 263: 15241–15244
   PubMed Web of Science ®Google Scholar
• Johnson D G, McCreary J M, Thompson W J, de Haen C. Inhibition of pancreatic islet phosphodiesterase by 2,4-diamino-5-cyano-6-bromopyridine. Adv. Cyclic Nucleotide Protein Phosphorylation Res. 1984; 16: 419
   Google Scholar
• Johnson L V, Walsh M L, Bockus B J, Chen L B. Monitoring of relative mitochondrial membrane potential in living cells by fluorescence microscopy. J. Cell Biol. 1981; 88: 526–535
   PubMed Web of Science ®Google Scholar
• Jones R J, Sharkis S J, Miller C B, Rowinsky E K, Burke P J, May W S. Bryostatin 1, a unique biologic response modifier: Anti-leukemic activity. in vitro. Blood 1990; 75: 1319–1323
   PubMed Web of Science ®Google Scholar
• Jones R L, Wilson N H, Armstrong R A. Characterization of thromboxane receptors in human platelets. Adv. Exp. Med. Biol. 1985; 192: 67–81
   PubMed Web of Science ®Google Scholar
• Joost H G, Habberfield A D, Simpson I A, Laurenza A, Seamon K B. Activation of adenylate cyclase and inhibition of glucose transport in rat adipocytes by forskolin analogues: Structural determinants for distinct sites of action. Mol. Pharmacol. 1988; 33: 449–453
   PubMed Web of Science ®Google Scholar
• Joost H G, Steinfelder H J. Forskolin inhibits insulin-stimulated glucose transport in rat adipose cells by a direct interaction with the glucose transporter. Mol. Pharmacol. 1987; 31: 279–283
   PubMed Web of Science ®Google Scholar
• Jori A, Carrara M C, Garattini S. Importance of noradrenaline synthesis for the interaction between desipramine and reserpine. J. Pharm. Pharmacol. 1966; 18: 619–620
   PubMed Web of Science ®Google Scholar
• Jungmann R A, Lee S, DeAngelo A B. Translocation of cytoplasmic protein kinase and cyclic adenosine monophosphate-binding protein to intracellular acceptor sites. Adv. Cyclic Nucleotide Res. 1975; 5: 281–306
   PubMedGoogle Scholar
• Kahlife K, Zannad F, Brunotte F, Belhadj K, Julliere Y, Iannascoli F. Placebo-controlled study of oral enoximone in congestive heart failure with initial and final intravenous hemodynamic evaluation. Am. J. Cardiol. 1987; 60: 75C–79C
   PubMed Web of Science ®Google Scholar
• Kaliner M, Austen K F. Cyclic nucleotides and modulation of effector systems of inflammation. Biochem. Pharmacol. 1974; 23: 763–771
   PubMed Web of Science ®Google Scholar
• Kariya T, Wille L J, Dage R C. Biochemical studies on the mechanism of cardiotonic activity of MDL 17,043. J. Cardiovasc. Pharmacol. 1982; 4: 509–514
   PubMed Web of Science ®Google Scholar
• Kariya T, Willie L J, Dage R C. Studies on the mechanism of the cardiotonic activity of MDL 19205: Effects on several biochemical systems. J. Cardiovasc. Pharmacol. 1984; 6: 50–55
   PubMed Web of Science ®Google Scholar
• Kase H, Iwahashi K, Matsuda Y. K-252a, a potent inhibitor of protein kinase C from microbial origin. J. Antibiot. (Tokyo) 1986; 39: 1059–1065
   PubMed Web of Science ®Google Scholar
• Kase H, Iwahashi K, Nakanishi S, Matsuda Y, Yamada K, Takahashi M. K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases. Biochem. Biophys. Res. Commun. 1987; 142: 436–4.4.0
   PubMed Web of Science ®Google Scholar
• Kashiwagi A, Huecksteadt T P, Foley J E. The regulation of glucose transport by cAMP stimulators via three different mechanisms in rat and human adipocytes. J. Biol. Chem. 1983; 258: 13685–13692
   PubMedGoogle Scholar
• Katoh N, Raynor R L, Wise B C, Schatzman R C, Turner R S, Helfman D M. Inhibition by melittin of phospholipid-sensitive and calmodulin-sensitive Ca2+-dependent protein kinases. Biochem. J. 1982; 202: 217–224
   PubMed Web of Science ®Google Scholar
• Katsaros D, Ally S, Cho-Chung Y S. Site-selective cyclic AMP analogues are antagonistic to estrogen stimulation of growth and protooncogene expression in human breast-cancer cells. Int. J. Cancer 1988; 41: 863–867
   PubMed Web of Science ®Google Scholar
• Kauffman R F, Crowe V G, Utterback B G, Robertson D W. LY 195115: A potent, selective inhibitor of cyclic nucleotide phosphodiesterase located in the sarcoplasmic reticulum. Mol. Pharmacol. 1986; 30: 609–616
   PubMed Web of Science ®Google Scholar
• Kehr W, Debus G, Neumeister R. Effects of rolipram, a novel anti-depressant, on monoamine metabolism in rat brain. J. Neural Transm. 1985; 63: 1–12
   PubMed Web of Science ®Google Scholar
• Kendall D A, Nahorski S R. 5-Hydroxytryptamine-stimulated inositol phospholipid hydrolysis in rat cerebral cortex slices: Pharmacological characterization and effects of antidepressants. J. Pharmacol. Exp. Ther. 1985; 233: 473–479
   PubMed Web of Science ®Google Scholar
• Kennedy E D, Challis RAJ, Nahorski S R. Lithium reduces the accumulation of inositol polyphosphate second messengers following cholinergic stimulation of cerebral cortex slices. J. Neurochem. 1989; 53: 1652–1655
   PubMed Web of Science ®Google Scholar
• Kiang D T, Kennedy B J. Tamoxifen (Antiestrogen) therapy in advanced breast cancer. Ann. Intern. Med. 1977; 87: 687–690
   PubMed Web of Science ®Google Scholar
• Kikkawa U, Takai Y, Minakuchi R, Inohara S, Nishizuka Y. Calcium-activated, phospholipid-dependent protein kinase from rat brain. Sub-cellular distribution, purification, and properties. J. Biol. Chem. 1982; 257: 13341–13348
   PubMed Web of Science ®Google Scholar
• Klein H W, Kilmer S, Carlsen R C. Enhancement of peripheral nerve regeneration by pharmacological activation of the cyclic AMP second messenger system. Microsurgery 1989; 10: 122–125
   PubMed Web of Science ®Google Scholar
• Kobayashi E, Ando K, Nakano H, Tamaoki T. UCN-1028A, a novel and specific inhibitor of protein kinase C, from Cladosporium. J. Antibiot. (Tokyo) 1989a; 42: 153–155
   PubMed Web of Science ®Google Scholar
• Kobayashi E, Nakano H, Morimoto M, Tamaoki T. Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem. Biophys. Res. Cornmun. 1989b; 159: 548–553
   PubMed Web of Science ®Google Scholar
• Korczak B, Whale C, Kerbel R S. Possible involvement of Ca2+ mobilization and protein kinase C activation in the induction of spontaneous metastasis by mouse mammary adenocarcinoma cells. Cancer Res. 1989; 49: 2597–2602
   PubMed Web of Science ®Google Scholar
• Koréh K, Monaco M E. The relationship of hormone-sensitive and hormone-insensitive phosphatidylinositol to phosphatidylinositol 4, 5-bisphosphate in the WRK-1 cell. J. Biol. Chem. 1986; 261: 88–91
   PubMed Web of Science ®Google Scholar
• Kraft A S, Anderson W B. Phorbol esters increase the amount of Ca2+, phospholipid-dependent protein kinase associated with plasma membrane. Nature 1983; 301: 621–623
   PubMed Web of Science ®Google Scholar
• Kraft A S, Anderson W B, Cooper H L, Sando J J. Decrease in cytosolic calcium/phospholipid-dependent protein kinase activity following phorbol ester treatement of EL4 thymoma cells. J. Biol. Chem. 1982; 257: 13193–13196
   PubMed Web of Science ®Google Scholar
• Kraft A S, Smith J B, Berkow R L. Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60. Proc. Natl. Acad. Sci. USA 1986; 83: 1334–1338
   PubMed Web of Science ®Google Scholar
• Kramer I M, van der Bend R L, Tool ATJ, van Blitterswijk W J, Roos D, Verhoeven A J. 1-O-Hexadecyl-2-O-methylglycerol, a novel inhibitor of protein kinase C, inhibits the respiratory burst in human neutrophils. J. Biol. Chem. 1989; 264: 5876–5884
   PubMed Web of Science ®Google Scholar
• Krebs E G. Protein kinases. Curr. Top. Cell. Regul. 1972; 5: 99–133
   PubMedGoogle Scholar
• Kruse C H, Holden K G, Pritchard M L, Feild J A, Rieman D J, Greig R G. Synthesis and evaluation of multisubstrate inhibitors of an oncogene-encoded tyrosine-specific protein kinase. 1. J. Med. Chem. 1988; 31: 1762–1767
   PubMed Web of Science ®Google Scholar
• Kukovetz W R, Poch G. Inhibition of cyclic-3′,5′-nucleotidephosphodiesterase as a possible mode of action of papaverine and similarly acting drugs. Naunyn Schmiedebergs Arch. Pharmacol. 1970; 267: 189–194
   PubMedGoogle Scholar
• Kuo J F, Greengard P. Cyclic nucleotide-dependent protein kinases, IV. Widespread occurrence of adenosine 3′,5′-monophosphatedependent protein kinase in various tissues and phyla of the animal kingdom. Proc. Natl. Acad. Sci. USA 1969; 64: 1349–1355
   PubMed Web of Science ®Google Scholar
• Lal B, Dohadwalla A N, Dadkar N K, D'Sa A, de Souza N J. Trequinsin, a potent new antihypertensive vasodilator in the series of 2-(arylimino)-3-alkyl -9,10-dimethoxy- 3,4,6,7-tetrahydro-2H-pyrimido-[6,1-a]isoquinolin-4-ones. J. Med. Chem. 1984; 27: 1470–1480
   PubMed Web of Science ®Google Scholar
• Landis C A, Masters S B, Spada A, Pace A M, Bourne H R, Vallar L. GTPase inhibiting mutations activate the α chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989; 340: 692–696
   PubMed Web of Science ®Google Scholar
• Laurenza A, Khandelwal Y, De Souza N J, Rupp R H, Metzger H, Seamon K B. Stimulation of adenylate cyclase by water-soluble analogues of forskolin. Mol. Pharmacol. 1987; 32: 133–139
   PubMed Web of Science ®Google Scholar
• Laurenza A, McHugh Sutkowski E, Seamon K B. Forskolin: A specific stimulator of adenylyl cyclase or a diterpene with multiple sites of action. Trends Pharmacol. Sci. 1989; 10: 442–447
   PubMed Web of Science ®Google Scholar
• Lee T S, Saltsman K A, Ohashi H, King G L. Activation of protein kinase C by elevation of glucose concentration: Proposal for a mechanism in the development of diabetic vascular complications. Proc. Natl. Acad. Sci. USA 1989; 86: 5141–5145
   PubMed Web of Science ®Google Scholar
• Legha S S, Davis H L, Muggia F M. Hormonal therapy of breast cancer: New approaches and concepts. Ann. intern. Med. 1978; 88: 69–77
   PubMed Web of Science ®Google Scholar
• Levin R M, Weiss B. Binding of trifluoperazine to the calcium-dependent activator of cyclic nucleotide phosphodiesterase. Mol. Pharmacol. 1977; 13: 690–697
   PubMed Web of Science ®Google Scholar
• Levine M A, Jap T S, Mauseth R S, Downs R W, Spiegel A M. Activity of the stimulatory guanine nucleotide-binding proteins is reduced in erythrocytes from patients with pseudohypoparathyroidism and pseudopseudohypoparathyroidism: Biochemical, endocrine, and genetic analysis of Albright's hereditary osteodystrophy in six kindreds. J. Clin. Endocrinol. Metab. 1986; 62: 497–502
   PubMed Web of Science ®Google Scholar
• Levitzki A, Gilon C. Tyrphostins as molecular tools and potential antiproliferative drugs. Trends Pharmacol. Sci. 1991; 12: 171–174
   PubMed Web of Science ®Google Scholar
• Levy J, Teuerstein I, Marbach M, Radian S, Sharoni Y. Tyrosine protein kinase activity in the DMBA-induced rat mammary tumor: Inhibition by quercetin. Biochem. Biophys. Res. Commun. 1984; 123: 1227–1233
   PubMed Web of Science ®Google Scholar
• Lewin L M, Yannai Y, Sulimovici S, Kraicer P F. Studies on the metabolic role of myo-inositol. Distribution of radioactive myo-inositol in the male rat. Biochem. J. 1976; 156: 375–380
   PubMed Web of Science ®Google Scholar
• Likoff M J, Weber K T, Andrews V, Janicki J S, Wilson H, Rocci MLJ. Milrinone in the treatment of chronic cardiac failure: A controlled trial. Am. Heart J. 1985; 110: 1035–1042
   PubMed Web of Science ®Google Scholar
• Linée P, Quiniou M J, Lahouratate P, Forest M C. BRL 40696: A novel potent inhibitor of the cardiac sarcoplasmic reticulum-bound phosphodiesterase, with positive inotropic and lusitropic properties. Eur. J. Pharmacol. 1990; 183: 784–785
   Web of Science ®Google Scholar
• Lochrie M A, Simon M I. G protein multiplicity in eukaryotic signal transduction systems. Biochemistry 1988; 27: 4957–4965
   PubMed Web of Science ®Google Scholar
• Lockwood A H, Murphy S K, Borislow S, Lazarus A, Pendergast M. Cellular signal trarlsduction and the reversal of malignancy. J. Cell. Biochem. 1987; 33: 237–255
   PubMed Web of Science ®Google Scholar
• Loomis C R, Bell R M. Sangivamycin, a nucleoside analogue, is a potent inhibitor of protein kinase C. J. Biol. Chem. 1988; 263: 1682–1692
   PubMed Web of Science ®Google Scholar
• Lyall R M, Zilberstein A, Gazit A, Gilon C, Levitzki A, Schlessinger J. Tyrphostins inhibit epidermal growth factor (EGF)-receptor tyrosinekinase activity in living cells and EGF-stimulated cell proliferation. J. Biol. Chem. 1989; 264: 14503–14509
   PubMed Web of Science ®Google Scholar
• Mahoney C W, Hensey C E, Azzi A. Auranofin, gold thiomalate, and gold thioglucose inhibit protein kinase C. Biochem. Pharmacol. 1989; 38: 3383–3386
   PubMed Web of Science ®Google Scholar
• Margolis R U, Press R, Altszuler N, Stewart M A. Inositol production by the brain in normal and alloxan-diabetic dogs. Brain Res. 1971; 28: 535–539
   PubMed Web of Science ®Google Scholar
• Maxwell S A, Sacks P G, Gutterman J U, Gallick G E. Epidermal growth factor receptor protein-tyrosine kinase activity in human cell lines established from squamous carcinomas of the head and neck. Cancer Res. 1989; 49: 1130–1137
   PubMed Web of Science ®Google Scholar
• Mazzei G J, Katoh N, Kuo J F. Polymyxin B is a more selective inhibitor for phospholipid-sensitive Ca2+-dependent protein kinase than for calmodulin-sensitive Ca2+-dependent protein kinase. Biochem. Biophys. Res. Commun. 1982; 109: 1129–1133
   PubMed Web of Science ®Google Scholar
• Menkes I-IA, Baraban J M, Freed A N, Snyder S H. Lithium dampens neurotransmitter response in smooth muscle: Relevance to action in affective illness. Proc. Natl. Acad. Sci. USA 1986; 83: 5727–5730
   PubMed Web of Science ®Google Scholar
• Merrill AHJ, Sereni A M, Stevens V L, Hannun Y A, Bell R M, Kinkade JMJ. Inhibition of phorbol ester-dependent differentiation of human promyelocytic leukemic (HL-60) cells by sphinganine and other long-chain bases. J. Biol. Chem. 1986; 261: 12610–12615
   PubMed Web of Science ®Google Scholar
• Metzger H, Lindner E. The positive inotropic-acting forskolin, a potent adenylatecyclase activator. Arzneimittelforschung 1981; 31: 1248–1250
   PubMed Web of Science ®Google Scholar
• Meyer T, Regenass U, Fabbro D, Alteri E, Rosel J, Muller M. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity. Int. J. Cancer 1989; 43: 851–856
   PubMed Web of Science ®Google Scholar
• Mikashima H, Nakao T, Goto K. Y-590 (a new pyridazinone derivative), a potent anti-thrombotic agent. I. Effect on platelet function. Thromb. Res. 1983; 31: 599–609
   Web of Science ®Google Scholar
• Minana M, Felipo V, Grisolia S. Inhibition of protein kinase C induces differentiation in neuro-2a cells. Proc. Natl. Acad. Sci. USA 1990; 87: 4335–4339
   PubMed Web of Science ®Google Scholar
• Mitchell F E, Marais R M, Parker P J. The phosphorylation of protein kinase C as a potential measure of activation. Biochem. J. 1989; 261: 131–136
   PubMed Web of Science ®Google Scholar
• Mizuta T, Segawa T. Chronic effects of imipramine and lithium on 5-HT receptor subtypes in rat frontal cortex, hippocampus and choroid plexus: Quantitative receptor autoradiographic analysis. Jpn. J. Pharmacol. 1989; 50: 315–326
   PubMedGoogle Scholar
• Mizuta T, Segawa T. Effects of imipramine and lithium on 5-HT-receptor-stimulated phospholipase C in rat brain. Eur. J. Pharmacol. 1990; 183: 1897–1898
   Web of Science ®Google Scholar
• Mochly-Rosen D, Koshland DEJ. Domain structure and phosphorylation of protein kinase C. J. Biol. Chem. 1987; 262: 2291–2297
   PubMed Web of Science ®Google Scholar
• Modest E J, Noseda A, Daniel L W, Piantadosi C. Membrane-targeted ether lipid analogs with anti-neoplastic activity. Cancer Chemother. Pharmacol. 1989; 24(suppl.): S59
   Google Scholar
• Monaco M E, Woods D. Characterization of the hormone-sensitive phosphatidylinositol pool in WRK-1 cells. J. Biol. Chem. 1983; 258: 15125–15129
   PubMedGoogle Scholar
• Moncada S, Vane J R. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol. Rev. 1979; 30: 293–332
   Web of Science ®Google Scholar
• Moncada S, Whittle B J. Biological actions of prostacyclin and its pharmacological use in platelet studies. Adv. Exp. Med. Biol. 1985; 192: 337–358
   PubMed Web of Science ®Google Scholar
• Mong S, Hoffman K, Wu H, Crooker S T. Leukotriene-induced hydrolysis of inositol lipids in guinea pig lung: Mechanism of signal transduction for leukotriene-D4 receptors. Mol. Pharmacol. 1987; 31: 35–41
   PubMed Web of Science ®Google Scholar
• Morris-Natschke S, Surles J R, Daniel L W, Berens M E, Modest E J, Piantadosi C. Synthesis of sulfur analogues of alkyl lysophospholipid and neoplastic cell growth inhibitory properties. J. Med. Chem. 1986; 29: 2114–2117
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Palshof T, Patterson J, Battersby L. Tamoxifen in advanced breast cancer. Cancer Treat. Rev. 1978; 5: 131–141
   PubMed Web of Science ®Google Scholar
• Mugge A, Reupcke C, Scholz H. Increased myocardial α-adrenoceptor density in rats chronically treated with propranolol. Eur. J. Pharmacol. 1985; 112: 249–252
   PubMed Web of Science ®Google Scholar
• Muller B, Lugnier C, Stoclet J. Comparison of the effects of specific inhibitors of cyclic AMP phosphodiesterases III and IV on guinea pig left atria contractility. Eur. J. Pharmacol. 1990a; 183: 660–661
   Web of Science ®Google Scholar
• Muller B, Lugnier C, Stoclet J. Implication of cyclic AMP in the positive inotropic effects of cyclic GMP-inhibited cyclic AMP phosphodiesterase inhibitors on guinea pig isolated left atria. J. Cardiovasc. Pharmacol. 1990b; 15: 444–451
   PubMed Web of Science ®Google Scholar
• Murakami Y, Mizuno S, Hori M, Uehara Y. Reversal of transformed phenotypes by herbimycin A in src oncogene expressed rat fibroblasts. Cancer Res. 1988; 48: 1587–1590
   PubMed Web of Science ®Google Scholar
• Murali S, Uretsky B F, Valdes A M, Kolesar J A, Reddy P S. Acute hemodynamic and hormonal effects of CI-930, a new phosphodiesterase inhibitor, in severe congestive heart failure. Am. J. Cardiol. 1987; 59: 1356–1360
   PubMed Web of Science ®Google Scholar
• Nagata K, Nozawa Y. GTP-binding proteins in human platelets. Platelets 1990; 1: 67–79
   PubMedGoogle Scholar
• Nakamura S, Takeuchi F, Tomizawa T, Takasaki N, Kondo H, Yamamura H. Two separate tyrosine protein kinases in human platelets. FEBS Lett. 1985; 184: 56–59
   PubMed Web of Science ®Google Scholar
• Neer E L, Lok J M, Wolf L G. Purification and properties of the inhibitory guanine nucleotide regulatory unit of brain adenylate cyclase. J. Biol. Chem. 1984; 259: 14222–14229
   PubMed Web of Science ®Google Scholar
• Nelson C A, Seamon K B. Binding of [3H]forskolin to human platelet membranes. Regulation by guanyl-5′-yl imidodiphosphate, NaF, and prostaglandins El and D2. J. Biol. Chem. 1986; 261: 13469–13473
   PubMedGoogle Scholar
• Nemoz G, Prigent A, Moueqqit M, Fougier S, Macovschi O, Pacheco H. Selective inhibition of one of the cyclic AMP phosphodiesterases from rat brain by the neurotropic compound rolipram. Biochem. Pharmacol. 1985; 34: 2997–3000
   PubMed Web of Science ®Google Scholar
• New Names. Carbazeran. J. Am. Med. Assoc. 1980; 243: 787
   Google Scholar
• Newman M E, Lerer B. Post-receptor-mediated increases in adenylate cyclase activity after chronic antidepressant treatment: Relationship to receptor desensitization. Eur. J. Pharmacol. 1989; 162: 345–352
   PubMed Web of Science ®Google Scholar
• Nigg E A. Mechanisms of signal transduction to the cell nucleus. Adv. Cancer Res. 1990; 55: 271–310
   PubMedGoogle Scholar
• Nishizuka Y. The family of protein kinase C for signal transduction. J. Am. Med. Assoc. 1989; 262: 1826–1833
   PubMed Web of Science ®Google Scholar
• Nishizuka Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 1988; 334: 661–665
   PubMed Web of Science ®Google Scholar
• Nishizuka Y. The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature 1984; 308: 693–698
   PubMed Web of Science ®Google Scholar
• Nishizuka Y. Studies and perspectives of protein kinase C. Science 1986; 233: 305–312
   PubMed Web of Science ®Google Scholar
• Nishizuka Y. Studies and prospectives of the protein kinase C family for cellular regulation. Cancer 1989; 63: 1892–1903
   PubMed Web of Science ®Google Scholar
• Northup J K, Smigel M D, Sternweis P C, Gilman A G. The subunits of the stimulatory regulatory component of adenylate cyclase. Resolution of the activated 45,000-dalton (a) subunit. J. Biol. Chem. 1983; 258: 11369–11376
   PubMed Web of Science ®Google Scholar
• Nosek T M, Williams M F, Zeigler S T, Godt R E. Inositol trisphosphate enhances calcium release in skinned cardiac and skeletal muscle. Am. J. Physicl. 1986; 250: C807–0811
   Web of Science ®Google Scholar
• Nunn D L, Watson S P. A diacylglycerol kinase inhibitor, R59022, potentiates secretion by and aggregation of thrombin-stimulated human platelets. Biochem. J. 1987; 243: 809–813
   PubMed Web of Science ®Google Scholar
• O'Brian C A, Liskamp R M, Solomon D H, Weinstein I B. Inhibition of protein kinase C by tamoxifen. Cancer Res. 1985; 45: 2462–2465
   PubMed Web of Science ®Google Scholar
• Ogawara H, Akiyama T, Ishida J, Watanabe S, Suzuki K. A specific inhibitor for tyrosine protein kinase from pseudomonas. J. Antibiot. (Tokyo) 1986; 39: 606–608
   PubMed Web of Science ®Google Scholar
• Ohashi M, Kanai R, Nishino K, Sato T, Takayanagi I. Antagonistic effect of KC-404, a new anti-asthmatic agent, on leukotriene D4-induced contractile responses in isolated guinea pig smooth muscles. Prostaglandins 1986; 32: 875–888
   PubMed Web of Science ®Google Scholar
• Ohno S, Kawasaki H, Imajoh S, Suzuki K, Inagaki M, Yokokura K. Tissue-specific expression of three distinct types of rabbit protein kinase C. Nature 1987; 325: 161–166
   PubMed Web of Science ®Google Scholar
• Ohta H, Tanaka T, Hidaka H. Putative binding site(s) of 1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H-7) on protein kinase C. Biochem. Pharmacol. 1988; 37: 2704–2706
   PubMed Web of Science ®Google Scholar
• Olianas M C, Onali P, Neff N H, Costa E. Adenylate cyclase activity of synaptic membranes from rat striatum. Inhibition by muscarinic receptor agonists. Mol. Pharmacol. 1983; 23: 393–398
   PubMed Web of Science ®Google Scholar
• Omura S, Iwai Y, Hirano A, Nakagawa A, Awaya J, Tsuchya H. A new alkaloid AM-2282 of streptomyces origin. Taxonomy, fermentation, isolation and preliminary characterization. J. Antibiot. (Tokyo) 1977; 30: 275–282
   PubMed Web of Science ®Google Scholar
• Pagani E, Fort D J, Ezrin A M, Silver P J. In vitro cardiovascular phosphodiesterase inhibition and in vivo cardiovascular activity of milrinone in dogs. FASEB J. 1988; 2: A366
   Web of Science ®Google Scholar
• Palmer G C, Robinson G A, Manian A A, Sulser F. Modification by psychotropic drugs of the cyclic AMP response to norepinephrine in the rat brain. in vitro. Psychopharmacologia 1972; 23: 201–211
   PubMedGoogle Scholar
• Parenti M, Ceresoli G, Consolo S, Groppetti A. Cross-talk between different intracellular signalling pathways in the rat hippocampus. Cell Biol. Int. Rep. 1989; 13: 1177–1187
   PubMedGoogle Scholar
• Pascuzzi R M, Kim Y I. Lambert-Eaton syndrome. Semin. Neurol. 1990; 10: 35–41
   PubMed Web of Science ®Google Scholar
• Pearson J D, DeWald D B, Mathews W R, Mozier N M, Zurcher-Neely IIA, Heinrikson R L. Amino acid sequence and characterization of a protein inhibitor of protein kinase C. J. Biol. Chem. 1990; 265: 4583–4591
   PubMed Web of Science ®Google Scholar
• Pelosin J, Keramidas M, Souvignet C, Chambaz E M. Differential inhibition of protein kinase C subtypes. Biochem. Biophys. Res. Commun. 1990; 169: 1040–1048
   PubMed Web of Science ®Google Scholar
• Perico N, Remuzzi G. Changes in arachidonate biosynthesis and metabolism in normal pregnancy and preeclampsia. Hematologic Disorders in Maternal–Fetal Medicine, M Bern, F. Frigoletto. Wiley, New York 1990; 329–348
   Google Scholar
• Perrella F W. Characterization of phosphatidylinositol phospholipase C activity in human melanoma. Biochem. Biophys. Res. Commun. 1990; 166: 715–722
   PubMed Web of Science ®Google Scholar
• Petein M, Levine T B, Cohn J N. Hemodynamic effects of a new isotropic agent, piroximone (MDL 19205), in patients with chronic heart failure. J. Am. Coll. Cardiol. 1984; 4: 364–371
   PubMed Web of Science ®Google Scholar
• Pettit G R, Cherry L, Herald D, Doubek L, Delbert L, Herald C L. Isolation and structure of bryostatin II. J. Am. Chem. Soc. 1982; 104: 6846–6848
   Web of Science ®Google Scholar
• Pfaffinger P J, Martin J M, Hunter D D, Nathanson N M, Hille B. GTP-binding proteins couple cardiac muscarinic receptors to a K channel. Nature 1985; 317: 536–538
   PubMed Web of Science ®Google Scholar
• Piazzesi G, Morano I, Ruegg J C. Effect of sulmazole and pimobendan on contractility of skinned fibres from frog skeletal muscle. Arzneimittelforschung 1987; 37: 1141–1143
   PubMed Web of Science ®Google Scholar
• Poison J B, Krzanowski J J, Szentivanyi A. Inhibition of a high affinity cyclic AMP phosphodiesterase and relaxation of canine tracheal smooth muscle. Biochem. Pharmacol. 1982; 31: 3403–3406
   PubMed Web of Science ®Google Scholar
• Posner I, Gazit A, Gilon C, Levitzki A. Tyrphostins inhibit the epidermal growth factor receptor-mediated breakdown of phosphoinositides. FEBS Lett. 1989; 257: 287–291
   PubMed Web of Science ®Google Scholar
• Pribilla I, Kruger H, Buchner K, Otto H, Schiebler W, Tripier D. Heat-resistant inhibitors of protein kinase C from bovine brain. Eur. J. Biochem. 1988; 177: 657–664
   PubMedGoogle Scholar
• Przegalinski E, Bigajska K. Antidepressant properties of some phosphodiesterase inhibitors. Pol. J. Pharmacol. Pharm. 1983; 35: 233–240
   PubMedGoogle Scholar
• Quade N M, Burrows S D, Kobylarz D C, Weishaar R E, Evans D B. Effects of CI-914, a novel cardiotonic agent, on molecular forms of phosphodiesterase from ventricular muscle, coronary arteries and platelets. Pharmacologist 1984; 26: 145
   Google Scholar
• Racagni G, Perez J, Tinelli D, Bianchi E, Cagnoli C, Brunello N. Receptor modulation and cAMP dependent phosphorylation system after repeated antidepressant administration. Eur. J. Pharmacol. 1990; 183: 1
   PubMed Web of Science ®Google Scholar
• Radeke H H, Auf'mkolk B, Juppner H, Krohn H P, Keck E, Hesch R D. Multiple pre- and postreceptor defects in pseudohypoparathyroidism (a multicenter study with twenty four patients). J. Clin. Endocrinol. Metab. 1986; 62: 393–402
   PubMed Web of Science ®Google Scholar
• Ramachandran J, Ullrich A. Hormonal regulation of protein tyrosine kinase activity. Trends Pharmacol. Sci. 1987; 8: 28–31
   Web of Science ®Google Scholar
• Ramsdell J S, Pettit G R, Tashjian AHJ. Three activators of protein kinase C, bryostatins, dioleins and phorbol esters, show differing specificities of action on GH4 pituitary cells. J. Biol. Chem. 1986; 261: 17073–17080
   PubMedGoogle Scholar
• Randt C T, Judge M E, Bonnet K A, Quartermain D. Brain cyclic AMP and memory in mice. Pharmacol. Biochem. Behav 1982; 17: 677–680
   PubMed Web of Science ®Google Scholar
• Reeves M L, Leigh B K, England P J. The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors. Biochem. J. 1987; 241: 535–541
   PubMed Web of Science ®Google Scholar
• Renard M, Jacobs P, Dechamps P, Dresse A, Bernard R. Hemodynamic and clinical response to three-day infusion of sulmazol (AR-L 115 BS) in severe congestive heart failure. Chest 1983; 84: 408–413
   PubMed Web of Science ®Google Scholar
• Renshaw P F, Joseph N E, Leigh J S, Jr. Chronic dietary lithium induces increased levels of myo-inositol-l-phosphatase activity in rat cerebral cortex homogenates. Brain Res. 1986a; 380: 401–404
   PubMed Web of Science ®Google Scholar
• Renshaw P F, Summers J J, Renshaw C E, Hines K G, Leigh JS, Jr. Changes in the 31 P-NMR spectra of cats receiving lithium chloride systemically. Biol. Psychiatry 1986b; 21: 694–698
   PubMed Web of Science ®Google Scholar
• Reuter H. Calcium channel modulation by neurotransmitters, enzymes and drugs. Nature 1983; 301: 569–574
   PubMed Web of Science ®Google Scholar
• Ricouart A, Tartar A, Sergheraert C. Inhibition of protein kinase C by retro-inverso pseudosubstrate analogues. Biochem. Biophys. Res. Commun. 1989; 165: 1382–1390
   PubMed Web of Science ®Google Scholar
• Ritch P S, Glazer R I, Cunningham R E, Shackney S E. Kinetic effects of sangivamycin in sarcoma 180. in vitro. Cancer Res. 1981; 41: 1784–1788
   PubMed Web of Science ®Google Scholar
• Roebel L E, Dage R C, Cheng H C, Woodward J K. In vitro andin vivo assessment of the cardiovascular effects of the cardiotonic drug MDL 19205. J. Cardiovasc. Pharmacol. 1984; 6: 43–49
   PubMed Web of Science ®Google Scholar
• Ross C A, MacCumber M W, Glatt C E, Snyder S H. Brain phospholipase C isozymes: Differential mRNA localizations by in situ hybridization. Proc. Natl. Acad. Sci. USA 1989; 86: 2923–2927
   PubMed Web of Science ®Google Scholar
• Ross S B, Renyi A L. Inhibition of the uptake of tritiated catecholamines by antidepressant and related agents. Eur. J. Pharmacol. 1967; 2: 181–186
   PubMed Web of Science ®Google Scholar
• Rotenberg S A, Smiley S, Ueffing M, Krauss R S, Chen L B, Weinstein I B. Inhibition of rodent protein kinase C by the anticarcinoma agent dequalinium. Cancer Res. 1990; 50: 677–685
   PubMed Web of Science ®Google Scholar
• Roth G J, Stanford N, Majerus P W. Acetylation of prostaglandin synthase by aspirin. Proc. Natl. Acad. Sci. USA 1975; 72: 3073–3076
   PubMed Web of Science ®Google Scholar
• Ruppert D, Weithmann K U. HL 725, an extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation. in vitro. Life Sci. 1982; 31: 2037–2043
   PubMed Web of Science ®Google Scholar
• Schick H D, Berdel W E, Fromm M, Fink U, Jehn U, Ulm K. Cytotoxic effects of ether lipids and derivatives in human nonneoplastic bone marrow cells and leukemic cells. in vitro. 1987; Lipids 22: 904–910
   Google Scholar
• Schildkraut J J. The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am. J. Psychiatry 1965; 122: 509–522
   PubMed Web of Science ®Google Scholar
• Schildkraut J J. Pharmacology: The effects of lithium on biogenic amines. Lithium, Its Role in Psychiatric Research and Treatment, S Gershon, B Shopsin. Plenum Press, New York 1973; 51–73
   Google Scholar
• Schmidt B, Volk R, Schultz J E. Induction of central noradrenergic subsensitivity after long-term treatement of rats with rolipram. Naunyn Schmiedebergs Arch. Pharmacol. 1985; 329: R92
   Google Scholar
• Schmitz W, Scholz H, Scholz J, Steinfath M. Increase in IP3 pre-cedes a-adrenoceptor-induced increase in force of contraction in cardiac muscle. Eur. J. Pharmacol. 1987b; 140: 109–111
   PubMed Web of Science ®Google Scholar
• Schmitz W, Scholz H, Scholz J, Steinfath M, Lohse M, Puurunen J. Pertussis toxin, does not inhibit the al-adrenoceptor-mediated effect on inositol phosphate production in the heart. Eur. J. Pharmacol. 1987a; 134: 377–378
   PubMed Web of Science ®Google Scholar
• Schneider H H. Brain cAMP response to phosphodiesterase inhibitors in rats killed by microwave irradiation or decapitation. Biochem. Pharmacol. 1984; 33: 1690–1693
   PubMed Web of Science ®Google Scholar
• Schneider H H, Schmiechen R, Brezinski M, Seidler J. Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur. J. Pharmacol. 1986; 127: 105–115
   PubMed Web of Science ®Google Scholar
• Schoemaker R G, Debets JJM, Struyker-Boudier HAJ, Smits JFM. Beneficial hemodynamic effects of two weeks' milrinone treatment in conscious rats with heart failure. Eur. J. Pharmacol. 1990; 182: 527–535
   PubMed Web of Science ®Google Scholar
• Scholz H. Effects of beta- and alfa-adrenoceptor activators and adrenergic transmitter releasing agents on the mechanical activity of the heart. Handbook of Experimental Pharmacology, L Szekeres. Springer-Verlag, New York 1980; 54: 651–733, pt. I
   Google Scholar
• Schou M, Thompson K. Lithium prophylaxis of recurrent endogenous affective disorders. Lithium Research and Therapy, FN Johnson. Academic Press, London 1975; 63–84
   Google Scholar
• Schramm M, Selinger Z. Message transmission: Receptor controlled adenylate cyclase system. Science 1984; 225: 1350–1356
   PubMed Web of Science ®Google Scholar
• Scolnick E M, Papageorge A G, Shih T Y. Guanine nucleotide-binding activity as an assay for src protein of rat-derived murine sarcoma viruses. Proc. Natl. Acad. Sci. USA 1979; 76: 5355–5359
   PubMed Web of Science ®Google Scholar
• Scriven AJI, Lipkin D P, Anand I S, Sutton G C, Poole-Wilson P A. A comparison of hemodynamic effects of one-month oral captopril and enoximone treatment for severe congestive heart failure. Am. J. Cardiol. 1987; 60: 68C–71C
   PubMed Web of Science ®Google Scholar
• Seamon K B, Daly J W. Forskolin: Its biological and chemical properties. Adv. Cyclic Nucleotide Protein Phosphorylation Res. 1986; 20: 1–150
   PubMedGoogle Scholar
• Shahid M, Nicholson C D. Comparison of the inotropic and phosphodiesterase inhibitory effects org 30029, IBMX, milrinone and rolipram in rat and rabbit ventricular myocardium. Eur. J. Pharmacol. 1990; 183: 780–781
   Web of Science ®Google Scholar
• Shechter Y, Yaish P, Chorev M, Gilon C, Braun S, Levitzki A. Inhibition of insulin-dependent lipogenesis and anti-lipolysis by protein tyrosine kinase inhibitors. EMBO J. 1989; 8: 1671–1676
   PubMed Web of Science ®Google Scholar
• Sheppard H, Wiggan G, Tsien W H. Structure-activity relationships for inhibitors of phosphodiesterase from erythrocytes and other tissues. Adv. Cyclic Nucleotide Res. 1972; 1: 103–112
   PubMedGoogle Scholar
• Shih T Y, Papageorge A G, Stokes P E, Weeks M O, Scolnick E M. Guanine nucleotide-binding and autophosphorylating activities associated with the p21 src protein of Harvey murine sarcoma virus. Nature 1980; 287: 686–691
   PubMed Web of Science ®Google Scholar
• Shiraishi T, Domoto T, Imai N, Shimada Y, Watanabe K. Specific inhibitors of tyrosine-specific protein kinase, synthetic 4-hydroxycinnamamide derivatives. Biochem. Biophys. Res. Commun. 1987; 147: 322–328
   PubMed Web of Science ®Google Scholar
• Shiraishi T, Owada M K, Tatsuka M, Yamashita T, Watanabe K, Kakunaga T. Specific inhibitors of tyrosine-specific protein kinases: Properties of 4-hydroxycinnamamide derivatives. in vitro. Cancer Res. 1989; 49: 2374–2378
   PubMed Web of Science ®Google Scholar
• Silver P J, Harris A L, Fort D J, Perrone M H, Evans D B. Effects of the cardiotonic/vasodilator agents amrinone and milrinone on phosphodiesterase (PDE) isozymes and contractile force in guinea pig cardiac and vascular tissue. Fed. Proc. 1987; 46: 373
   Google Scholar
• Simpson AWM, Reeves M L, Rink T J. Effects of SK & F 94120, an inhibitor of cyclic nucleotide phosphodiesterase type III, on human platelets. Biochem. Pharmacol. 1988; 37: 2315–2320
   PubMed Web of Science ®Google Scholar
• Slater I H, Rathbun R C, Kattau R. Role of 5-hydroxytryptaminergic and adrenergic mechanism in antagonism of reserpine-induced hypothermia in mice. J. Pharm. Pharmacol. 1979; 31: 108–110
   PubMed Web of Science ®Google Scholar
• Smith P F, Thompson W J, de Haen C, Halonen M, Palmer J D, Johnson D G. Bronchodilator activity of a nonxanthine phosphodiesterase inhibitor; 2,4-diamino-5-cyano-6-bromopyridine (compound 1). J. Pharmacol. Exp. Ther. 1986; 237: 114–119
   PubMed Web of Science ®Google Scholar
• Souto M, Frances H, Lecrubier Y, Puech A J, Simon P. Antagonism by d, l-propranolol of imipramine effects in mice. Eur. J. Pharmacol. 1979; 60: 105–108
   PubMed Web of Science ®Google Scholar
• Sozzani S, Agwu D E, McCall C E, McPhail L C. In vitro inhibition of neutrophil protein kinase C by propranolol. Submitted 1991a
   Google Scholar
• Sozzani S, Agwu D E, McCall C E, O'Flaherty J T, Mantovani A, McPhail L C. Propranolol inhibits protein kinase C (PKC) and PKC-dependent responses in human neutrophils. FASEB J. 1991b; 5: A547
   Web of Science ®Google Scholar
• Spat A, Fabiato A, Rubin R P. Binding of inositol trisphosphate by a liver microsomal fraction. Biochem. J. 1986; 233: 929–932
   PubMed Web of Science ®Google Scholar
• Steffen R P, Eldon C M, Evans D B. The effect of the cardiotonic imazodan (CI-914) on myocardial and peripheral hemodynamics in the anesthetized dog. J. Cardiovasc. Pharmacol. 1986; 8: 520–526
   PubMed Web of Science ®Google Scholar
• Steinkraus V, Nose M, Scholz H, Thormahlen K. Time course and extent of αl-adrenoceptor density changes in rat heart after β-adrenoceptor blockade. Br. J. Pharmacol. 1989; 96: 441–449
   PubMed Web of Science ®Google Scholar
• Strathmann M, Wilkie T M, Simon M I. Diversity of the G-protein family: Sequences from five additional α subunits in the mouse. Proc. Natl. Acad. Sci. USA 1989; 86: 7407–7409
   PubMed Web of Science ®Google Scholar
• Suh P, Ryu S H, Moon K H, Suh H W, Rhee S G. Cloning and sequence of multiple forms of phospholipase C. Cell 1988a; 54: 161–169
   PubMed Web of Science ®Google Scholar
• Suh P, Ryu S H, Moon K H, Suh H W, Rhee S G. Inositol phospholipid-specific phospholipase C: Complete cDNA and protein sequences and sequence homology to tyrosine kinase-related oncogene products. Proc. Natl. Acad. Sci. USA 1988b; 85: 5419–5423
   PubMed Web of Science ®Google Scholar
• Sulser F. New perspectives on the mode of action of antidepressant drugs. Trends Pharmacol. Sci. 1979; 1: 92–94
   Web of Science ®Google Scholar
• Sulser F, Mobely P L. Regulation of central noradrenergic receptor function: New vistas on the mode of action of antidepressants. Neuroreceptors: Basic and Clinical Aspects. Raven Press, New York 1981; 312–322
   Google Scholar
• Suolinna E, Buchsbaum R N, Racker E. The effect of flavonoids on aerobic glycolysis and growth of tumor cells. Cancer Res. 1975; 35: 1865–1872
   PubMed Web of Science ®Google Scholar
• Suzdak P D, Browne R G. The effect of chronic in vivo infusion of forskolin on noradrenergic receptor sensitivity. Psychopharmacology 1985; 87: 464–467
   PubMed Web of Science ®Google Scholar
• Tagliaferri P, Katsaros D, Clair T, Neckers L, Robins R K, Cho-Chung Y S. Reverse transformation of Harvey murine sarcoma virus-transformed NIH/3T3 cells by site-selective cyclic AMP analogs. J. Biol. Chem. 1988; 263: 409–416
   PubMed Web of Science ®Google Scholar
• Takahashi I, Nakanishi S, Kobayashi E, Nakano H, Suzuki K. Tamaoki T. Hypericin and pseudohypericin specifically inhibit protein kinase C: Possible relation to their antiretroviral activity. Biochem. Biophys. Res. Commun. 1989; 165: 1207–1212
   PubMed Web of Science ®Google Scholar
• Tamaoki T, Nomoto H, Takahashi I, Kato Y, Morimoto M, Tomita F. Staurosporine, a potent inhibitor of phospholipid/Ca++ dependent protein kinase. Biochem. Biophys. Res. Commun. 1986; 135: 397–402
   PubMed Web of Science ®Google Scholar
• Taylor C W. Receptor regulation of calcium entry. Trends Pharmacol. Sci. 1987; 8: 79–80
   Web of Science ®Google Scholar
• Terasaki W L, Appleman M M. The role of cyclic GMP in the regulation of cyclic AMP hydrolysis. Metabolism 1975; 24: 311–319
   PubMed Web of Science ®Google Scholar
• Tobia A, Falotico R, Simon D, Combs D, Moore J, Bell S. Bemoradan: A novel orally potent inotrope/peripheral vasodilator with beneficial hemodynamics in congestive heart failure patients. Eur. J. Pharmacol. 1990; 183: 776–777
   Web of Science ®Google Scholar
• Tortora G, Ciardiello F, Ally S, Clair T, Salomon D S, Cho-Chung Y S. Site-selective 8-chloroadenosine 3′,5′-cyclic monophosphate inhibits transformation and transforming growth factor a production in Ki-ras-transformed rat fibroblasts. FEBS Lett. 1989; 242: 363–367
   PubMed Web of Science ®Google Scholar
• Tortora G, Clair T, Cho-Chung Y S. An antisense oligodeoxynucleotide targeted against the type IIb regulatory subunit mRNA of protein kinase inhibits cAMP-induced differentiation in HL-60 leukemia cells without affecting phorbol ester effects. Proc. Natl. Acad. Sci. USA 1990; 87: 705–708
   PubMed Web of Science ®Google Scholar
• Tortora G, Tagliaferri P, Clair T, Colamonici O, Neckers L M, Robins R K, Cho-Chung Y S. Site-selective cAMP analogs at micromolar concentrations induce growth arrest and differentiation of acute promyelocytic, chronic myelocytic, and acute lymphocytic human leukemia cell lines. Blood 1988; 71: 230–233
   PubMed Web of Science ®Google Scholar
• Traxler P, Lydon N, Geissler J, Meyer T, Regenass U, Roesel J. Thiazolidine-diones. A novel type of selective inhibitors of protein tyrosine kinase. Cancer Chemother. Pharmacol. 1989; 24 (Suppl. 2): S87
   Google Scholar
• Uehara Y, Fukazawa H, Murakami Y, Mizuno S. Irreversible inhibition of v-src tyrosine kinase activity by herbimycin A and its abrogation by sulfhydryl compounds. Biochem. Biophys. Res. Commun. 1989a; 163: 803–809
   PubMed Web of Science ®Google Scholar
• Uehara Y, Hori M, Takeuchi T, Umezawa H. Phenotypic change from transformed to normal induced by benzoquinoid ansamycins ac-companies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus. Mol. Cell. Biol. 1986; 6: 2198–2206
   PubMed Web of Science ®Google Scholar
• Uehara Y, Hori M, Takeuchi T, Umezawa H. Screening of agents which convert ‘transformed morphology’ of Rous sarcoma virus-infected rat kidney cells to ‘normal morphology’: Identification of an active agent as herbimycin and its inhibition of intracellular SRC kinase. Jpn. J. Cancer Res. 1985; 76: 672–675
   PubMedGoogle Scholar
• Uehara Y, Murakami Y, Sugimoto Y, Mizuno S. Mechanism of re-version of Rous sarcoma virus transformation by herbimycin A: Reduction of total phosphotyrosine levels due to reduced kinase activity and increased turnover of p60v-src 1. Cancer Res. 1989b; 49: 780–785
   PubMed Web of Science ®Google Scholar
• Umezawa H, Imoto M, Sawa T., Isshiki K, Matsuda N, Uchida T. Studies on a new epidermal growth factor-receptor kinase inhibitor, erbstatin, produced by MH435-hF3. J. Antibiot. (Tokyo) 1986; 39: 170–173
   PubMed Web of Science ®Google Scholar
• Umezawa K, Hori T, Tajima H, Imoto M, Isshiki K, Takeuchi T. Inhibition of epidermal growth factor-induced DNA synthesis by tyrosine kinase inhibitors. FEBS Lett. 1990; 260: 198–200
   PubMed Web of Science ®Google Scholar
• Vallar L, Spada A, Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 1987; 330: 566–568
   PubMed Web of Science ®Google Scholar
• Vallejo M, Jackson T, Lightman S, Hanley M R. Occurrence and extracellular actions of inositol pentakis- and hexakisphosphate in mammalian brain. Nature 1987; 330: 656–658
   PubMed Web of Science ®Google Scholar
• van Blitterswijk W J, van der Bend R L, Kramer I M, Verhoeven A J, Hilkmann H, de Widt J. A metabolite of an antineoplastic ether phospholipid may inhibit transmembrane signalling via protein kinase C. Lipids 1987; 22: 842–846
   PubMed Web of Science ®Google Scholar
• van Mee J C. Effects of some cardiotonic agents on contractility of skinned fibers from mammalian heart. Arzneimittelforschung 1987; 37: 679–682
   PubMed Web of Science ®Google Scholar
• Vargaftig B B. The inhibition of cyclo-oxygenase of rabbit platelets by aspirin is prevented by salicylic acid and by phenanthrolines. Eur. J. Pharmacol. 1978; 50: 231–241
   PubMed Web of Science ®Google Scholar
• Vaughan Williams E M. Is phosphodiesterase inhibition arrhythmogenic? Electrophysiologic effects in pithed rats and in normoxic and hypoxic rabbit atria of enoximone, a new cardiotonic agent. J. Clin. Pharmacol. 1987; 27: 91–100
   PubMed Web of Science ®Google Scholar
• Vergara J, Tsien R Y, Delay M. Inositol 1,4,5-trisphosphate: A possible chemical link in excitation-contraction coupling in muscle. Prot. Natl. Acad. Sci. USA 1985; 82: 6352–6356
   PubMed Web of Science ®Google Scholar
• Verma S C, McNeill J H. Biochemical and mechanical effects of phenylephrine on the heart. Eur. J. Pharmacol. 1976; 36: 447–450
   PubMed Web of Science ®Google Scholar
• Vincent A, Lang B, Newson-Davis J. Autoimmunity to the voltage-gated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder. Trends Neurosci. 1989; 12: 496–502
   PubMed Web of Science ®Google Scholar
• Vinci G, Tabilio A, Deschamps J F, Van Haeke D, Henri A, Guichard J. Immunological studies of in vitro maturation of human megakaryocytes. Br. J. Haematol. 1984; 56: 589–605
   PubMed Web of Science ®Google Scholar
• Vogler W R, Olson A C, Okamoto S, Somberg L B, Glasser L. Experimental studies on the role of alkyl lysophospholipids in autologous bone marrow transplantation. Lipids 1987; 22: 919–924
   PubMed Web of Science ®Google Scholar
• Volpe P, Salviati G, Di Virgilio F, Pozzan T. Inositol 1,4,5-trisphosphate induces calcium release from sarcoplasmic reticulum of skeletal muscle. Nature 1985; 316: 347–349
   PubMed Web of Science ®Google Scholar
• von der Leyen H, Brunkhorst D, Meyer W, Scholz H. Positive isotropic and chronotropic effects and phosphodiesterase III inhibition of new cardiotonic agents. Circulation 1987; 76 (suppl. 4): IV-155
   Web of Science ®Google Scholar
• von der Leyen H, Schmitz W, Scholz H, Scholz J. New positive isotropic agents acting by phosphodiesterase inhibition or alphaladrenergic stimulation. Pharmacol. Res. 1989; 21: 329–337
   PubMed Web of Science ®Google Scholar
• Wachtel H. Characteristic behavioral alterations in rats induced by Rolipram and other selective adenosine cyclic 3′,5′-monophosphate phosphodiesterase inhibitors. Psychopharmacology 1982; 77: 309–316
   PubMed Web of Science ®Google Scholar
• Wachtel H. Neurotropic effects of the optical isomers of the selective adenosine cyclic 3′,5′-monophosphate phosphodiesterase inhibitor Rolipram in rats. in vivo. J. Pharm. Pharmacol. 1983a; 35: 440–444
   PubMed Web of Science ®Google Scholar
• Wachtel H. Potential antidepressant activity of Rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitors. Neuropharmacology 1983b; 22: 267–272
   PubMed Web of Science ®Google Scholar
• Wachtel H, Loschmann P. Effects of forskolin and cyclic nucleotides in animal models predictive of antidepressant activity: Interactions with Rolipram. Psychopharmacology 1986; 90: 430–435
   PubMed Web of Science ®Google Scholar
• Wachtel H, Schneider H H. Rolipram, a novel antidepressant drug, reverses the hypothermia and hypokinesia of monoamine-depleted mice by an action beyond postsynaptic monoamine receptors. Neuropharmacology 1986; 25: 1119–1126
   PubMed Web of Science ®Google Scholar
• Waldmeier P C. Noradrenergic transmission in depression under-or overfunction. Pharmacopsychiatria 1981; 14 (suppl. 1): 3–9
   Google Scholar
• Watanabe K, Gola M. Forskolin interaction with voltage-dependent K channels in Helix is not mediated by cyclic nucleotides. Neurosci. Lett. 1987; 78: 211–216
   PubMed Web of Science ®Google Scholar
• Weber K T, Janicki J S, Jain M C. Piroximone (MDL 19,205) in the treatment of unstable and stable chronic cardiac failure. Am. Heart J. 1987; 114: 805–813
   PubMed Web of Science ®Google Scholar
• Weinstock R S, Wright H N, Spiegel A M, Levine M A, Moses A M. Olfactory dysfunction in humans with deficient guanine nucleotide-binding protein. Nature 1986; 322: 635–636
   PubMed Web of Science ®Google Scholar
• Weishaar R E, Burrows S D, Kobylarz D C, Quade M M, Evans D B. Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents. Biochem. Pharmacol. 1986; 35: 787–800
   PubMed Web of Science ®Google Scholar
• Weishaar R E, Cain M H, Bristol J A. A new generation of phosphodiesterase inhibitors: Multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J. Med. Chem. 1985; 28: 537–545
   PubMed Web of Science ®Google Scholar
• Weishaar R E, Kobylarz-Singer D C, Steffen R P, Kaplan H R. Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility. Circ. Res. 1987; 61: 539–547
   PubMed Web of Science ®Google Scholar
• Weiss M J, Wong J R, Ha C S, Bleday R, Salem R R, Steele GDJ. Dequalinium, a topical antimicrobial agent, displays anticarcinoma activity based on selective mitochondrial accumulation. Proc. Natl. Acad. Sci. USA 1987; 84: 5444–5448
   PubMed Web of Science ®Google Scholar
• Wells J N, Miller J R. Methylxanthine inhibitors of phosphodiesterases. Methods Enzymol. 1988; 159: 489–496
   PubMed Web of Science ®Google Scholar
• Whitworth P, Kendall D A. Lithium selectively inhibits muscarinic receptor-stimulated inositol tetrakisphosphate accumulation in mouse cerebral cortex slices. J. Neurochem. 1988; 51: 258–265
   PubMed Web of Science ®Google Scholar
• Wollschlager H, Drexler H, Lollgen H, Just H. The hemodynamic effect of AR-L 115 BS, a new positive-inotropic agent, in patients with left ventricular failure. Arzneimittelforschung 1981; 31: 248–250
   PubMed Web of Science ®Google Scholar
• Worley P F, Baraban J M, Colvin J S, Snyder S H. Inositol trisphosphate receptor localization in brain: Variable stoichiometry with protein kinase C. Nature 1987; 325: 159–161
   PubMed Web of Science ®Google Scholar
• Worley P F, Baraban J M, De Souza E B, Snyder S H. Mapping second messenger systems in the brain: Differential localizations of adenylate cyclase and protein kinase C. Proc. Natl. Acad. Sci. USA 1986; 83: 4053–4057
   PubMed Web of Science ®Google Scholar
• Worley P F, Heller W A, Snyder S H, Baraban J M. Lithium blocks a phosphoinositide-mediated cholinergic response in hippocampal slices. Science 1988; 239: 1428–1429
   PubMed Web of Science ®Google Scholar
• Yaish P, Gazit A, Gilon C, Levitzki A. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 1988; 242: 933–935
   PubMed Web of Science ®Google Scholar
• Yarden Y. Growth factor receptor tyrosine kinases. Annu. Rev. Biochem. 1988; 57: 443–478
   PubMed Web of Science ®Google Scholar
• Zeller E, Stief H J, Pflug B, Sastre-y-Hernandez M. Results of a phase II study of the antidepressant effect of Rolipram. Pharmacopsychiatry 1984; 17: 188–190
   PubMed Web of Science ®Google Scholar
• Zipperle G, Butzer F, Dieterich H A, Heinrich F. A double-blind dose response comparison of oral enoximone and placebo for congestive heart failure. Am. J. Cardiol. 1987; 60: 72C–74C
   PubMed Web of Science ®Google Scholar